The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC Lymphoma SPORE) Career Development Program (CDP) is to develop knowledgeable, well-trained scientists experienced in multidisciplinary research for future studies in translational lymphoma research. The provision of ample opportunities for training and career enhancement is a top priority of the University of Iowa and Mayo Clinic scientific communities. The extensive research and training base available at these two institutions provides strong support for the UI/MC Lymphoma SPORE CDP. The primary objectives of the CDP are to: (1) train young investigators (senior postdoctoral fellows and young faculty) in translational, multidisciplinary clinical or basic lymphoma research;(2) redirect established investigators to further lymphoma research;and (3) collaborate with investigators from other institutions who are interested in pursuing a research career in translational lymphoma research. During the initial funding period 6 young investigators received awards. Their work has led to the discovery of novel translocations, potential new methods of antigen presentation, and new treatments that are now being tested in clinical trials. During the next funding period, the UI/MC Lymphoma SPORE will maintain: (1) a stringent candidate selection system;(2) comprehensive trainee guidance by a mentor and other investigators from both sites;(3) support through a scientific mentor group (the Individual Trainee Advisory Committee) comprised of investigators from both sites with expertise in each trainee's area of interest;(4) multi-disciplinary research courses and on-going training activities such as the Multidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites;(5) encouragement of collaboration with Investigator Group meetings at both sites;(6) encouragement of collaboration with investigators at both Iowa and Mayo and (7) opportunities for research enhancement through the Developmental Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-09
Application #
8076893
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$93,690
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598
Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182

Showing the most recent 10 out of 387 publications